|
Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 2
STATEMENT OF NEED
Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to treatment-related adverse events and impaired quality of life, all of which increase the challenges of... |
|
|
Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.
STATEMENT OF NEED
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana... |
|
|
New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia
Gain expert insight on new treatment approaches to improve outcomes for patients with immune thrombocytopenia, including individualized treatment for patients who relapse and strategies to alleviate and improve supportive care. This discussion is led by Howard Liebman, MD, Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine, and Allison Miller lmahiyerobo, MSN, APN, Advanced Practice Nurse at Hematology and Oncology Physicians of Englewood. Star... |
|
|
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
STATEMENT OF NEED
T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic... |
|
|
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multiple Myeloma
Discover new developments in sequential treatment and clinical findings, evaluate strategies to manage and monitor adverse events, and initiating therapy for patients with relapsed/refractory Multiple Myeloma, and much more! Leading oncologist Shaji Kumar, Mayo Clinic Cancer Center, presents this in-depth discussion. Start the activity now!
STATEMENT OF NEED
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramed... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLL
Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including BTK inhi... |
|
|
Through the Patient/Family Looking Glass: Perspectives in Treatment Planning by Disease Compartments for Pediatric Neuroblastoma
Target Audience
The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.
Statement of Need/Program Overview
With an ever-improving understanding of clinical and biological risk factors, treatment strategies for pediatric neuroblastoma have become more... |
|
|
Clinical Cases in MS: Primary Care Perspectives
Target Audience
This activity is intended for Primary care clinicians (physicians, NPs, PAs), nurses, neurology clinicians (physicians, NPs, PAs), advanced practice nurses and other healthcare providers who may participate in the assessment and care of individuals with MS.
Program Overview
Although there is no medication that can fully prevent or reverse the neurologic deterioration associated with multiple sclerosis (MS), the use of disease-modifying therapy (DMT) is widely recommended t... |
|
|
Clinical Cases in MS: Neurology Specialty Perspectives
Target Audience
This activity is intended for Primary care clinicians (physicians, NPs, PAs), nurses, neurology clinicians (physicians, NPs, PAs), advanced practice nurses and other healthcare providers who may participate in the assessment and care of individuals with MS.
Program Overview
Although there is no medication that can fully prevent or reverse the neurologic deterioration associated with multiple sclerosis (MS), the use of disease-modifying therapy (DMT) is widely recommended t... |
|
|
Multiple The 15th Annual Johns Hopkins Sclerosis Symposium Series
Program Overview
Although there is no medication that can fully prevent or reverse the neurologic deterioration associated with multiple sclerosis (MS), the use of disease-modifying therapy (DMT) is widely recommended to favorably impact prognosis and reduce disability. The number of DMTs now approved by the US Food and Drug Administration has grown substantially, resulting in more options for patients, but also increasing the complexity of starting, stopping, and switching treatments for h... |
|
|
Activity Title: The Future of Early-Stage NSCLC Treatment: Updates on Neoadjuvant Immunotherapy Program Name: Paradigm - A1067 NSCLC - 38591P9Eef2 - 2021-11-29-01
TARGET AUDIENCE:
This activity has been designed to address the educational needs of medical oncologists. It may also be of benefit to other healthcare professionals who manage patients with non-small cell lung cancer (NSCLC).
PROGRAM OVERVIEW:
Approximately half of all patients with early-stage NSCLC relapse after treatment with curative intent, which typically includes surgery, radiation, and adjuvant systemic therapy. The success of immune checkpoint inhibitor (ICI) treatment of advanc... |
|
|
New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma
Target Audience
The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.
Activity Overview
Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many var... |
|
|
Expert Illustrations & Commentaries™: Roles and Rationales for BCMA-Directed Therapies in Multiple Myeloma
Target Audience
This educational program is directed toward medical oncologists/hematologists, and other oncology HCPs involved in the treatment of multiple myeloma. Advanced practitioners, nurses, pharmacists, and other healthcare professionals interested in multiple myeloma will be invited to participate.
Program Overview
This Expert Illustrations and CommentariesTM online activity is a video-based program in which 2 experts discuss emerging treatments in multiple myeloma (MM), name... |
|
|
Medical Crossfire®: Sequencing of Disease Modifying Therapies – Optimizing Outcomes in Patients with Multiple Sclerosis
Target Audience
This educational activity is directed toward neurologists and MS subspecialists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with MS will be invited to participate.
Program Overview
Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system characterized by demyelination and neurodegenerative progression. Most patients with MS experience relapses and r... |
|
|
Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2
Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.
What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on ... |
|
|
Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management
B-cell non-Hodgkin lymphoma management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy—the majority of which do so because of adverse events (AEs)—and data suggest that the management of AEs is not consistent with recommendations. Moreover... |
|
|
Community Practice Connections ®: New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma
Target Audience
The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.
Program Overview
Nearly all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variable... |
|
|
Updates in Mantle Cell Lymphoma
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin ly... |
|
|
Ace the Case: Disease Progression in a 72-Year-Old Woman With Chronic Lymphocytic Leukemia Previously Treated With Venetoclax-Obinutuzumab
This activity utilizes a case study to discuss treatment options for an older patient with relapsed chronic lymphocytic leukemia (CLL). |
|
|
Ace the Case: Disease Progression in a 65-Year-Old Man With Previously Treated Mantle Cell Lymphoma
This activity utilizes a case study to discuss treatment options for an older patient with relapsed mantle cell lymphoma (MCL). |
|
|
Novel Therapeutic Strategies in Myeloma – Module 4
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of recent therapeutic advances for patients with newly diagnosed or relapsed multiple myeloma and the mechanisms by which novel therapies work.
Learning Objective
Upon completion of this activity, participants should be b... |
|
|
Ace the Case: 71-Year-Old Woman With IgG Lambda Multiple Myeloma at Third Relapse
This activity utilizes a case study to discuss treatment options for multiple myeloma (MM) patients who have relapsed from previous therapies. |
|
|
Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show
Multiple myeloma management has advanced significantly in recent years, providing new hope for myeloma patients but creating new challenges for health care providers. Using an engaging and entertaining game show format (think Who Wants to Be a Millionaire), this activity tests players’ knowledge of current and emerging myeloma patient care best practices. Along the way—using a range of multimedia prompts and hints—the game presents information on several fast-evolving areas of myeloma ca... |
|
|
Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, advanced oncology certified nurse practitioners, and other health care providers involved in the care of patients with multiple myeloma.
Program Overview
Multiple myeloma management has advanced significantly in recent years, providing new hope for myeloma patients but creating new challenges for health care providers. Using an engaging and entertaining game show format (think Who Wants t... |
|
|
Show Me Your Care Plan!™ Nursing Strategies to Support Continuity of Care in the Treatment of Multiple Sclerosis
Target Audience
This educational program is directed toward nurses who are involved in the management of patients with multiple sclerosis. Neurologists, nurse practitioners, physician assistants, MS specialists, and other HCPs are invited to participate.
Program Overview
Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS) characterized by demyelination and neurodegenerative progression. Most patients with MS experience relapses and remission of neurolog... |
|
|
Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy
TARGET AUDIENCE:
Hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with LBCL.
PROGRAM OVERVIEW:
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive c... |
|
|
Identification of Relapsed ALL
Target Audience
The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the first in a series of four modules on relapsed/refractory acute lymphocytic leukemia (ALL). Module 1 focuses on identification of relapsed ALL. This education is presented by Dr. Reshma Ramlal from the University of Kentucky Mar... |
|
|
Treatment of Relapsed/Refractory Ph+ ALL
Target Audience
The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the second in a series of four educational activities focusing on the treatment of relapsed/refractory ALL. Dr. Jessica Leonard, from Oregon Health and Science University, discusses diagnoses and treatment options, and will wal... |
|
|
Can We Prevent C diff infection relapses with Vancomycin Prophlyaxis?
Clostridiodes difficile infections are a significant burden to patients and the healthcare community. Novel approaches are being investigated to help mitigate relapses. This application-based continuing pharmacy education will review recent infectious disease literature with a unique spin. Join us to learn how machine based learning can inform clinical trials and the recent updates on C diff infections. |
|
|
Codependency: Causes, Consequences and Cures
In this course, the author offers in-depth and in-person strategies for therapists to use in working with clients who present with the characteristic behavior patterns of codependency. Clients are usually unaware of the underlying codependency that is often responsible for the symptoms they’re suffering. Starting with emphasis on the delicate process of building a caring therapeutic relationship with these clients, the author guides readers through the early shame-inducing parenting styles t... |
|